Skip to main content

Table 3 Reactivity in ELISA of sera from mothers of groups I and II

From: 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block

Antigen

Systemic lupus erythematosus

Sjögren's syndrome

Asymptomatic

 

Group I (%)

Group II (%)

P

Group I (%)

Group II (%)

P

Group I (%)

Recombinant Ro52 protein

97

66

0.009*

67

98

0.027*

31

1–13 MASAARLTMMWEE

77

46

0.084

47

58

 

31

10–25 MWEEVTPICLDPFVE

0

14

 

0

0

 

0

12–35 EEVTCPICLDPFVEPVSIECGHSF

10

16

 

20

8

 

13

25–40 EPVSIECGHSFCQECI

0

13

 

10

0

 

6

34–56 SFCQECISQVGKGGGSVCAVCRQ

0

1

 

7

0

 

13

38–53 ECISQVGKGGGSVCAV

3

4

 

7

0

 

0

50–64 VCAVCRQRFLLKNLR

25

3

 

13

5

 

6

63–79 LRPNRQLANMVNNLKEI

0

6

 

0

3

 

0

77–94 KEISQEAREGTQGERCAV

18

1

 

3

0

 

0

93–116 AVHGERLHLFCEKDGKALCWVCAQ

40

12

 

10

9

 

0

94–109 VHGERLHLFCEKDGKA

3

13

 

0

0

 

0

107–122 GKALCWVCAQSRKHRD

69

28

0.023*

47

33

 

13

107–126 GKALCWVCAQSRKHRDHAMV

37

7

0.062

13

8

 

13

121–137 RDHAMVPLEEAAQEYQE

0

4

 

0

0

 

0

135–151 YQEKLQVALGELRRKQE

3

14

 

0

0

 

0

149–166 KQELAEKLEVEIAIKRAD

0

12

 

0

1

 

0

164–180 RADWKKTVETQKSRIHA

0

9

 

0

0

 

6

178–193 IHAEFVQQKNFLVEEE

3

14

 

0

0

 

0

191–208 EEEQRQLQELEKDEREQL

0

0

 

0

0

 

0

206–224 EQLRILGEKEAKLAQQSQA

0

1

 

7

0

 

9

222–235 SQALQELISELDRRCHS

17

3

 

23

1

 

6

236–250 CHSSALELLQEVIIV

27

6

 

10

7

 

0

249–264 IVLERSESWNLKDLDI

0

5

 

7

0

 

0

262–279 LDITSPELRSVCHVPGLK

0

0

 

0

0

 

0

277–292 GLKKMLRTCAVHITLD

83

49

0.049*

40

24

 

6

290–304 TLDPDTANPWLILSE

0

7

 

7

0

 

0

302–317 LSEDRRQVRLGDTQQS

10

2

 

7

0

 

0

314–328 TQQSIPGNEERFDSY

0

9

 

0

9

 

0

326–340 DSYPMVLGAQHFHSG

0

0

 

0

0

 

0

337–352 FHSGKHYWEVDVTGKE

23

11

 

3

12

 

6

350–367 GKEAWDLGVCRDSVRRKG

0

1

 

0

0

 

9

365–382 RKGHFLLSSKSGFWTIWL

77

47

0.054

50

33

 

25

380–396 IWLWNKQKYEAGTYPQT

0

5

 

0

2

 

0

394–412 PQTPLHLQVPPCQVGIFLD

18

1

 

3

10

 

0

411–423 LDYEAGMVSFYNI

0

2

 

0

0

 

0

422–438 NITDHGSLIYSFSECAF

16

2

 

0

0

 

0

436–451 CAFTGPLRPFFSPGFN

13

7

 

13

10

 

0

447–463 SPGFNDGGKNTAPLTLC

8

9

 

0

6

 

0

463–475 CPLNIGSQGSTDY

0

7

 

7

1

 

0

Ro60 PROTEIN

80

67

 

67

99

0.022*

31

1–23 MEESVNQMQPLNEKQIANSQDGY

15

6

 

17

1

 

6

18–38 NSQDGYVWQVTDMNRLHRFLC

32

11

 

20

1

0.097

0

21–41 DGYVWQVTDMNRLHRFLCFGS

64

27

0.044*

23

38

 

0

304–324 VCEKLCNEKLLKKARIHPFHI

50

18

 

27

4

 

13

495–518 KLIVCGMTSNGFTIADPDDRGMLD

10

24

0.058

7

11

0.079

13

524–538 TGALDVIRNFTLDMI

10

17

 

3

9

 

0

La PROTEIN

93

30

<0.0001*

40

68

 

13

  1. The 192 samples described in Table 1 were systematically tested in at least two independent tests. Only the IgG response was tested. Patients' sera were diluted 1:1,000. To be tested in the ELISA, peptide 21–41 of Ro60 protein was conjugated to ovalbumin. The sera were considered positive when optical density ≥0.3. Statistically significant differences between groups were determined by Student's t test. *P < 0.05 considered significant.